SUN-385 Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-Based 3d Modeling

Winzenrieth R, Ominsky M, Wang Y, Humbert L, Weiss R

Journal of the Endocrine Society8 May 2020

PMCIDPMC7209294PepBankPUB-92695262

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased total hip areal BMD versus placebo at 18 months.
In plain wordsIn women with osteoporosis, abaloparatide increased total hip bone density more than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal hip areal BMD versus placebo
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Areal BMD change
4.2%
abaloparatide
Source sentences
Summary
At 18 months, total hip areal BMD was significantly increased in both the ABL and TPTD groups (P<0.001 vs PBO), with gains from baseline significantly greater with ABL versus TPTD (4.2% vs 3.3%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526201
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased total hip areal BMD more than teriparatide at 18 months.
In plain wordsIn women with osteoporosis, abaloparatide increased total hip bone density more than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal hip areal BMD versus teriparatide
Study
n = 500
Comparator
teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Areal BMD change
4.2%
abaloparatide
Areal BMD change
3.3%
teriparatide
Source sentences
Summary
At 18 months, total hip areal BMD was significantly increased in both the ABL and TPTD groups (P<0.001 vs PBO), with gains from baseline significantly greater with ABL versus TPTD (4.2% vs 3.3%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526203
03HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated higher trabecular vBMD gains with abaloparatide than placebo at month 18.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater trabecular bone density gains with abaloparatide than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseModeled trabecular vBMD versus placebo
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Trabecular vBMD change
9%
abaloparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526205
04HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated similar trabecular vBMD gains with abaloparatide and teriparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated similar trabecular bone density gains with abaloparatide and teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeModeled trabecular vBMD versus teriparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Trabecular vBMD change
9%
abaloparatide
Trabecular vBMD change
9%
teriparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526207
05HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated greater cortical thickness gains with abaloparatide than placebo.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater cortical thickness gains with abaloparatide than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseModeled cortical thickness versus placebo
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical thickness change
1.5%
abaloparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526209
06HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated similar cortical thickness gains with abaloparatide and teriparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated similar cortical thickness gains with abaloparatide and teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeModeled cortical thickness versus teriparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical thickness change
1.5%
abaloparatide
Cortical thickness change
1.5%
teriparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526211
07HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated greater cortical vBMD gains with abaloparatide than placebo.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater cortical bone density gains with abaloparatide than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseModeled cortical vBMD versus placebo
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical vBMD change
1.3%
abaloparatide
Cortical vBMD change
−0.2%
placebo
Source sentences
Summary
In contrast, cortical vBMD was significantly increased from baseline with ABL (1.3%) compared with PBO (-0.2%) and TPTD (0.4%) at month 18 (both P<0.05 vs ABL).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526213
08HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated greater cortical vBMD gains with abaloparatide than teriparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater cortical bone density gains with abaloparatide than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseModeled cortical vBMD versus teriparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical vBMD change
1.3%
abaloparatide
Cortical vBMD change
0.4%
teriparatide
Source sentences
Summary
In contrast, cortical vBMD was significantly increased from baseline with ABL (1.3%) compared with PBO (-0.2%) and TPTD (0.4%) at month 18 (both P<0.05 vs ABL).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526214
09HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated greater cortical surface BMD gains with abaloparatide than placebo.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater cortical surface bone density gains with abaloparatide than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseModeled cortical surface BMD versus placebo
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical surface BMD change
2.8%
abaloparatide
Cortical surface BMD change
−0.2%
placebo
Source sentences
Summary
Cortical sBMD, the product of cortical thickness and vBMD, was also increased with ABL (+2.8%) versus both PBO (-0.2%) and TPTD (+1.8%) at month 18 (both P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526216
10HumanRandomized controlled trialEfficacy outcome
DXA-based modeling of women with osteoporosis estimated greater cortical surface BMD gains with abaloparatide than teriparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater cortical surface bone density gains with abaloparatide than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseModeled cortical surface BMD versus teriparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical surface BMD change
2.8%
abaloparatide
Cortical surface BMD change
1.8%
teriparatide
Source sentences
Summary
Cortical sBMD, the product of cortical thickness and vBMD, was also increased with ABL (+2.8%) versus both PBO (-0.2%) and TPTD (+1.8%) at month 18 (both P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526217
11HumanObservational studyEfficacy outcome
In women with osteoporosis, teriparatide increased total hip areal BMD versus placebo at 18 months.
In plain wordsIn women with osteoporosis, teriparatide increased total hip bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip areal BMD versus placebo
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Areal BMD change
3.3%
teriparatide
Source sentences
Summary
At 18 months, total hip areal BMD was significantly increased in both the ABL and TPTD groups (P<0.001 vs PBO), with gains from baseline significantly greater with ABL versus TPTD (4.2% vs 3.3%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526202
12HumanObservational studyEfficacy outcome
In women with osteoporosis, teriparatide produced a smaller total hip areal BMD increase than abaloparatide at 18 months.
In plain wordsIn women with osteoporosis, teriparatide increased total hip bone density less than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTotal hip areal BMD versus abaloparatide
Study
n = 500
Comparator
abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Areal BMD change
3.3%
teriparatide
Areal BMD change
4.2%
abaloparatide
Source sentences
Summary
At 18 months, total hip areal BMD was significantly increased in both the ABL and TPTD groups (P<0.001 vs PBO), with gains from baseline significantly greater with ABL versus TPTD (4.2% vs 3.3%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526204
13HumanObservational studyEfficacy outcome
DXA-based modeling of women with osteoporosis estimated higher trabecular vBMD gains with teriparatide than placebo at month 18.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater trabecular bone density gains with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseModeled trabecular vBMD versus placebo
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Trabecular vBMD change
9%
teriparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526206
14HumanObservational studyEfficacy outcome
DXA-based modeling of women with osteoporosis estimated similar trabecular vBMD gains with teriparatide and abaloparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated similar trabecular bone density gains with teriparatide and abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeModeled trabecular vBMD versus abaloparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Trabecular vBMD change
9%
teriparatide
Trabecular vBMD change
9%
abaloparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526208
15HumanObservational studyEfficacy outcome
DXA-based modeling of women with osteoporosis estimated greater cortical thickness gains with teriparatide than placebo.
In plain wordsIn women with osteoporosis, DXA analysis estimated greater cortical thickness gains with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseModeled cortical thickness versus placebo
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical thickness change
1.5%
teriparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526210
16HumanObservational studyEfficacy outcome
DXA-based modeling of women with osteoporosis estimated similar cortical thickness gains with teriparatide and abaloparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated similar cortical thickness gains with teriparatide and abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeModeled cortical thickness versus abaloparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical thickness change
1.5%
teriparatide
Cortical thickness change
1.5%
abaloparatide
Source sentences
Summary
Similar increases from baseline were observed with ABL and TPTD for both trabecular vBMD (9%) and cortical thickness (1.5%) at month 18 (both P<0.001 vs PBO).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526212
17HumanObservational studyEfficacy outcome
DXA-based modeling of women with osteoporosis estimated smaller cortical vBMD gains with teriparatide than abaloparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated smaller cortical bone density gains with teriparatide than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseModeled cortical vBMD versus abaloparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical vBMD change
0.4%
teriparatide
Cortical vBMD change
1.3%
abaloparatide
Source sentences
Summary
In contrast, cortical vBMD was significantly increased from baseline with ABL (1.3%) compared with PBO (-0.2%) and TPTD (0.4%) at month 18 (both P<0.05 vs ABL).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526215
18HumanObservational studyEfficacy outcome
DXA-based modeling of women with osteoporosis estimated smaller cortical surface BMD gains with teriparatide than abaloparatide.
In plain wordsIn women with osteoporosis, DXA analysis estimated smaller cortical surface bone density gains with teriparatide than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseModeled cortical surface BMD versus abaloparatide
Study
Homo sapiensn = 500
Postmenopausal women with osteoporosis in the ACTIVE trial, with DXA-based 3D estimates of proximal femur bone properties
Comparator
abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (Homo sapiens).
Measurements
Cortical surface BMD change
1.8%
teriparatide
Cortical surface BMD change
2.8%
abaloparatide
Source sentences
Summary
Cortical sBMD, the product of cortical thickness and vBMD, was also increased with ABL (+2.8%) versus both PBO (-0.2%) and TPTD (+1.8%) at month 18 (both P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, a 3D modeling approach was applied to DXA images from patients in the ACTIVE trial to estimate cortical and trabecular changes in the proximal femur over 18 months of treatment with placebo (PBO), ABL, or TPTD.
Summary · context
A subset of 750 patients, 250 from each of the treatment groups in ACTIVE (PBO, ABL, TPTD) with non-missing BMD data were randomly selected with data stratified by study site and patient race/ethnicity.
Report a problemFND-9269526218

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.